PortalPublikationenFSTL5 is a marker of poor prognosis in non-WNT/non-SHH medul...

FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.

Standard

FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. / Remke, Marc; Hielscher, Thomas; Korshunov, Andrey; Northcott, Paul A; Bender, Sebastian; Kool, Marcel; Westermann, Frank; Benner, Axel; Cin, Huriye; Ryzhova, Marina; Sturm, Dominik; Witt, Hendrik; Haag, Daniel; Toedt, Grischa; Wittmann, Andrea; Schöttler, Anna; von Bueren, André; André, O; Rutkowski, Stefan; Rutkowski, Stefan; Scheurlen, Wolfram; Kulozik, Andreas E; Taylor, Michael D; Lichter, Peter; Pfister, Stefan M.

in: J CLIN ONCOL, Jahrgang 29, Nr. 29, 29, 2011, S. 3852-3861.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Remke, M, Hielscher, T, Korshunov, A, Northcott, PA, Bender, S, Kool, M, Westermann, F, Benner, A, Cin, H, Ryzhova, M, Sturm, D, Witt, H, Haag, D, Toedt, G, Wittmann, A, Schöttler, A, von Bueren, A, André, O, Rutkowski, S, Rutkowski, S, Scheurlen, W, Kulozik, AE, Taylor, MD, Lichter, P & Pfister, SM 2011, 'FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.', J CLIN ONCOL, Jg. 29, Nr. 29, 29, S. 3852-3861. <http://www.ncbi.nlm.nih.gov/pubmed/21911727?dopt=Citation>

APA

Remke, M., Hielscher, T., Korshunov, A., Northcott, P. A., Bender, S., Kool, M., Westermann, F., Benner, A., Cin, H., Ryzhova, M., Sturm, D., Witt, H., Haag, D., Toedt, G., Wittmann, A., Schöttler, A., von Bueren, A., André, O., Rutkowski, S., ... Pfister, S. M. (2011). FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J CLIN ONCOL, 29(29), 3852-3861. [29]. http://www.ncbi.nlm.nih.gov/pubmed/21911727?dopt=Citation

Vancouver

Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J CLIN ONCOL. 2011;29(29):3852-3861. 29.

Bibtex

@article{446955d403df4704993f5b2329080044,
title = "FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.",
abstract = "Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors.",
keywords = "Humans, Cohort Studies, Child, Prognosis, Survival Analysis, Disease-Free Survival, Gene Expression Profiling, Kaplan-Meier Estimate, Tumor Markers, Biological/biosynthesis/genetics, Brain Neoplasms/*genetics/metabolism/*pathology, Follistatin-Related Proteins/biosynthesis/*genetics, Medulloblastoma/*genetics/metabolism/*pathology, Microarray Analysis, Real-Time Polymerase Chain Reaction, Humans, Cohort Studies, Child, Prognosis, Survival Analysis, Disease-Free Survival, Gene Expression Profiling, Kaplan-Meier Estimate, Tumor Markers, Biological/biosynthesis/genetics, Brain Neoplasms/*genetics/metabolism/*pathology, Follistatin-Related Proteins/biosynthesis/*genetics, Medulloblastoma/*genetics/metabolism/*pathology, Microarray Analysis, Real-Time Polymerase Chain Reaction",
author = "Marc Remke and Thomas Hielscher and Andrey Korshunov and Northcott, {Paul A} and Sebastian Bender and Marcel Kool and Frank Westermann and Axel Benner and Huriye Cin and Marina Ryzhova and Dominik Sturm and Hendrik Witt and Daniel Haag and Grischa Toedt and Andrea Wittmann and Anna Sch{\"o}ttler and {von Bueren}, Andr{\'e} and O Andr{\'e} and Stefan Rutkowski and Stefan Rutkowski and Wolfram Scheurlen and Kulozik, {Andreas E} and Taylor, {Michael D} and Peter Lichter and Pfister, {Stefan M}",
year = "2011",
language = "English",
volume = "29",
pages = "3852--3861",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "29",

}

RIS

TY - JOUR

T1 - FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.

AU - Remke, Marc

AU - Hielscher, Thomas

AU - Korshunov, Andrey

AU - Northcott, Paul A

AU - Bender, Sebastian

AU - Kool, Marcel

AU - Westermann, Frank

AU - Benner, Axel

AU - Cin, Huriye

AU - Ryzhova, Marina

AU - Sturm, Dominik

AU - Witt, Hendrik

AU - Haag, Daniel

AU - Toedt, Grischa

AU - Wittmann, Andrea

AU - Schöttler, Anna

AU - von Bueren, André

AU - André, O

AU - Rutkowski, Stefan

AU - Rutkowski, Stefan

AU - Scheurlen, Wolfram

AU - Kulozik, Andreas E

AU - Taylor, Michael D

AU - Lichter, Peter

AU - Pfister, Stefan M

PY - 2011

Y1 - 2011

N2 - Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors.

AB - Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors.

KW - Humans

KW - Cohort Studies

KW - Child

KW - Prognosis

KW - Survival Analysis

KW - Disease-Free Survival

KW - Gene Expression Profiling

KW - Kaplan-Meier Estimate

KW - Tumor Markers, Biological/biosynthesis/genetics

KW - Brain Neoplasms/genetics/metabolism/pathology

KW - Follistatin-Related Proteins/biosynthesis/genetics

KW - Medulloblastoma/genetics/metabolism/pathology

KW - Microarray Analysis

KW - Real-Time Polymerase Chain Reaction

KW - Humans

KW - Cohort Studies

KW - Child

KW - Prognosis

KW - Survival Analysis

KW - Disease-Free Survival

KW - Gene Expression Profiling

KW - Kaplan-Meier Estimate

KW - Tumor Markers, Biological/biosynthesis/genetics

KW - Brain Neoplasms/genetics/metabolism/pathology

KW - Follistatin-Related Proteins/biosynthesis/genetics

KW - Medulloblastoma/genetics/metabolism/pathology

KW - Microarray Analysis

KW - Real-Time Polymerase Chain Reaction

M3 - SCORING: Journal article

VL - 29

SP - 3852

EP - 3861

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 29

M1 - 29

ER -